Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Abstract: Disclosed is a distributed computer system and a method of operation thereof. The distributed computer system includes a plurality of worker nodes. The collective learning of the worker nodes is managed within the distributed computer system. The operation of distributed computer system is coordinated by employing a distributed ledger arrangement. The distributed computer system comprises a monitoring arrangement to provide learning parameters to the worker nodes by way of executing smart contract. Each of the worker nodes is operable to train a computing model based on the learning parameters and a set of training data. The monitoring arrangement provides a reward to at least one of the worker nodes for training the computing model. The reward is determined based on a number and frequency of intermediary computing models provided by a given worker node to a remainder of the worker nodes; and a quality of the intermediary computing models.

Abstract: A method for characterizing impacts experienced by a user comprises receiving a plurality of types of data, determining an impact score for the user, and communicating the impact score to the user. The plurality of types of data includes impact data associated with one or more impacts experienced by the user, and demographic data associated with the user. The impact score characterizes an effect on the user from the one or more impacts.

Abstract: A mouth guard senses an impact event and generates impact data associated with the impact event. The impact data can be analyzed to determine whether the impact event is a true impact event or a false impact event. The impact data can be analyzed by a trained model. The impact data can be labeled after independently determining whether the impact event was a true impact event or a false impact event. The labeled impact data can be used to update the model.

Abstract: The present disclosure is directed to substrates or topsheets having repeating patterns of apertures for absorbent articles. Each of the repeat units comprises at least three apertures.

Abstract: An absorbent article comprises a three-dimensional liquid permeable topsheet. The topsheet comprises a first layer comprising a hydrophobic material and a second layer comprising a hydrophilic material. The first layer is joined to the second layer. The topsheet comprises a plurality of recesses, a plurality of projections, and a plurality of land areas. The land areas surround at least a majority of the plurality of projections and a plurality of the recesses. The absorbent article comprises a liquid impermeable backsheet, an acquisition material, an absorbent core disposed at least partially intermediate the acquisition material and the liquid impermeable backsheet, and an indicia. The indicia is on the acquisition material or the liquid permeable topsheet. The indicia is visible from a wearer-facing side of the absorbent article. The indicia is different color than the acquisition material or the liquid permeable topsheet.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Abstract: Methods for reducing myeloid-derived suppressor cells and activating T cells in a patient and for treating a patient suffering from a solid tumor are described. The methods entail administering a CD3/CD33 T cell engager.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).

Abstract: The present disclosure is directed to substrates or topsheets having repeating patterns of apertures for absorbent articles. Each of the repeat units comprises at least three apertures.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).

Abstract: The present disclosure is directed to absorbent articles with substrates or topsheets having repeating patterns of apertures comprising a plurality of repeat units. Each of the repeat units comprises at least three apertures.

Abstract: The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.

Abstract: Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl oxidase-like 2 (LOXL2), and agents, compositions, kits, assay systems, and devices for use with such methods.

Abstract: The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (MMP9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.